NCT07177937

A Study of DXC014 in Patients With Advanced Solid Tumors.

An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of DXC014 for Injection in Patients With Advanced Solid Tumors.

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Hangzhou DAC Biotechnology Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC014 in patients with Advanced Solid Tumors.

Conditions

• Small Cell Lung Cancer
• Melanoma
• Prostate Cancer
• Other Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	DXC014	Dose Escalation DXC014, Cohort Expansion DXC014

Timeline

• Start date: 2025-10-20
• Primary completion: 2030-10-20
• Completion: 2030-10-20
• First posted: 2025-09-17
• Last updated: 2025-09-22

Locations

3 sites across 1 country: China